bcl6 degrader bms-986458
Generic: BCL6 Degrader BMS-986458
bcl6 degrader bms-986458: 1 clinical trial tracked.
bcl6 degrader bms-986458 evidence translation
What we can confirm
1 tracked trial
No verified listed developer
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about bcl6 degrader bms-986458, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence0 indications · 1 study sponsors
Related indications
No linked indication is available.
Study sponsors
Clinical Trials (1)
A Phase 1/2, Multi-Center, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BMS-986458, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed/Refractory Non-Hodgkin Lymphomas (R/R NHL)
Primary endpoint: Number of participants with adverse events (AEs)
InterventionalRandomizedopen460 targetStarted 2023-12Completion 2028-1050 sites · Chile, China, France, Germany…Bristol-Myers Squibb